Global Newborn Screening for SMA and SCID Market Strategic Research Report

Scope of the Report

The global Newborn Screening for SMA and SCID market size is predicted to grow from US$ 188 million in 2025 to US$ 392 million in 2032; it is expected to grow at a CAGR of 11.2% from 2026 to 2032.

Newborn screening is the practice of testing every newborn for certain harmful or potentially fatal disorder that isn’t otherwise apparent at birth.Newborn screening is the practice of testing every newborn for certain harmful or potentially fatal disorder that isn’t otherwise apparent at birth.

Severe combined immunodeficiency (SCID) is a group of rare disorders caused by mutations in different genes involved in the development and function of infection-fighting immune cells. Infants with SCID appear healthy at birth but are highly susceptible to severe infections.

Spinal muscular atrophy (SMA) is a group of hereditary diseases that progressively destroys motor neurons—nerve cells in the brain stem and spinal cord that control essential skeletal muscle activity such as speaking, walking, breathing, and swallowing, leading to muscle weakness and atrophy.

Global key players providing newborn screening for SMA and SCID are Perkinelmer, Thermo Fisher, ImmunoIVD, and Labsystems Diagnostics. The top four companies together hold 90% of the market share, with the largest vendor being Perkinelmer with 60% of the market share. The global companies providing newborn SMA and SCID screening are mainly located in North America and Europe, with North America holding the largest market share with 60%. In terms of product categories, kits dominate the market with 60% market share, followed by instruments and software with 35% and 5% market share, respectively. In terms of applications, SCID screening holds a 65% market share, while SMA screening is 35%.

This report presents a comprehensive overview of the global Newborn Screening for SMA and SCID market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Instruments
• Kits
• Software

Segment by players, this report covers

• Perkinelmer
• Thermo Fisher
• ImmunoIVD
• Labsystems Diagnostics

Segment by Application

• SCID Screening
• SMA Screening

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Newborn Screening for SMA and SCID market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in SCID Screening, SMA Screening evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact